Affimed Establishes Scientific Advisory Board
June 30 2022 - 4:00PM
Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a
clinical-stage immuno-oncology company committed to giving patients
back their innate ability to fight cancer, announced today the
establishment of a Scientific Advisory Board (SAB) of renowned
experts in their respective fields to provide scientific and
clinical guidance on the development of Affimed’s innate cell
engagers (ICE®) programs.
This newly formed advisory board includes the following
scientific and clinical experts:
- Stephen M. Ansell, MD,
PhD, Professor of Medicine, Division of Hematology at the
Mayo Clinic, with extensive expertise in B-cell malignancies,
including both Hodgkin and non-Hodgkin lymphomas
- Todd A. Fehniger, MD,
PhD, Professor of Medicine, Washington University School
of Medicine, an internationally recognized leader in natural killer
(NK) cell immunotherapy, stem cell transplantation and
lymphomas
- Prof. Dr. Ulrike
Köhl, Professor of Immuno-Oncology, University of Leipzig,
director of the Fraunhofer Institute for Cell Therapy and
Immunology, Leipzig as well as director of the Institute of
Cellular Therapeutics, Hannover Medical School, Germany, a leading
expert in the development and manufacturing of cell and gene
therapies in cancer with a special focus on NK cells
- Sandro Matosevic,
PhD, Assistant Professor, College of Pharmacy at Purdue
University, with expertise in the development and use of natural
killer cells in cancer treatment, with various patents on the
engineering and utilization of NK cells in cancer immunotherapy and
solid tumors
“We are honored to have the participation of this distinguished
group of leading scientists and physicians on our Scientific
Advisory Board and look forward to their advice as we advance our
technology, preclinical and clinical programs,” said Dr. Arndt
Schottelius, Chief Scientific Officer at Affimed. “This advisory
board brings together invaluable expertise in hematological and
solid cancers as well as the biology of NK cells and their
application to further the development of our novel and highly
potent innate immune cell-engaging therapies.”
Dr. Fehniger of Washington University School of Medicine added,
“This is an exciting time for innate immunity therapy development.
Affimed has a robust pipeline and promising clinical data
validating the research approach. I look forward to working with
the company and the other members of the SAB in expediting
timelines to make these promising therapies available to cancer
patients.”
The SAB members are leaders in a broad range of areas relevant
to Affimed's approach to developing cancer therapies including
immuno-oncology, the biology of NK cells, lymphomas, leukemias, and
solid tumors.
To learn more about the members of the new Scientific Advisory
Board, please visit the “About Us” section of Affimed’s website at
www.affimed.com.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology
company committed to give patients back their innate ability to
fight cancer by actualizing the untapped potential of the innate
immune system. The Company’s proprietary ROCK® platform enables a
tumor-targeted approach to recognize and kill a range of
hematologic and solid tumors, enabling a broad pipeline of
wholly-owned and partnered single agent and combination therapy
programs. The ROCK® platform predictably generates customized
innate cell engager (ICE®) molecules, which use patients’ immune
cells to destroy tumor cells. This innovative approach enabled
Affimed to become the first company with a clinical-stage ICE®.
Headquartered in Heidelberg, Germany, with offices in New York,
NY, Affimed is led by an experienced team of biotechnology and
pharmaceutical leaders united by a bold vision to stop cancer from
ever derailing patients’ lives. For more about the Company, its
people, pipeline and partners, please visit www.affimed.com.
Investor Relations Contact
Alexander FudukidisDirector, Investor
RelationsE-Mail: a.fudukidis@affimed.comTel.: +1 (917)
436-8102
Media Contact
Mary Beth Sandin Vice President, Marketing and
CommunicationsE-Mail: m.sandin@affimed.com Tel.: +1 (484)
888-8195
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024